{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:18:21Z","timestamp":1791206301397,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010017","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,11,24]],"date-time":"2015-11-24T00:00:00Z","timestamp":1448323200000}}],"reference-count":90,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010017.pub2","type":"journal-article","created":{"date-parts":[[2015,11,24]],"date-time":"2015-11-24T14:18:15Z","timestamp":1448374695000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anti-TNF agents for paediatric psoriasis"],"prefix":"10.1002","volume":"2019","author":[{"given":"Gloria","family":"Sanclemente","sequence":"first","affiliation":[{"name":"Universidad de Antioquia; Grupo de Investigaci\u00f3n Dermatol\u00f3gica (GRID); Carrera 25 A #1 A Sur 45, Of 2026 Torre Medica El Tesoro Medell\u00edn Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Murphy","sequence":"additional","affiliation":[{"name":"Sheffield Children's NHS Foundation Trust; Department of Dermatology, Sheffield Children's Hospital; Sheffield UK S10 2JF"},{"name":"Sheffield Teaching Hospitals NHS Foundation Trust; Department of Dermatology; Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Contreras","sequence":"additional","affiliation":[{"name":"Universidad de Antioquia; Department of Pediatrics, School of Medicine; Carrera 51d N\u00ba 62-29 Facultad de Medicina Medellin Antioquia Colombia 050010"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermenegildo","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"The University of Nottingham; c\/o Cochrane Skin Group; A103, King's Meadow Campus Lenton Lane Nottingham UK NG7 2NR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bonfill Cosp","sequence":"additional","affiliation":[{"name":"CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP); Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau); Sant Antoni Maria Claret 167 Pavilion 18 Barcelona Catalunya Spain 08025"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,11,24]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD010017.pub2-BIB0001|cit1","first-page":"323","article-title":"Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis","volume":"20","author":"Landells","year":"2010","journal-title":"European Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD010017.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaad.2010.02.060","article-title":"Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial","volume":"64","author":"Langley","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010017.pub2-BIB0003|cit3","first-page":"251","article-title":"Etanercept in children and adolescents with psoriasis (ABP08-119)","volume":"19","author":"Levy","year":"2005","journal-title":"Journal of the European Academy of Dermatology & Venereology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010017.pub2-BIB0004|cit4","first-page":"AB11","article-title":"Safety and efficacy of etanercept treatment in children and adolescents with plaque psoriasis: 96-week results of open-label extension study","volume":"3","author":"Paller","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD010017.pub2-BIB0005|cit5","first-page":"AB195","article-title":"A 12 week phase 3 study of efficacy and safety of etanercept therapy in children and adolescents with moderate to severe plaque psoriasis","volume":"56","author":"Paller","year":"2007","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD010017.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/j.jaad.2009.11.001","article-title":"Subgroup analyses of etanercept in pediatric patients with psoriasis","volume":"63","author":"Paller","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD010017.pub2-BIB0007|cit7","first-page":"52","article-title":"Interim results of a long-term safety and tolerability study of etanercept treatment in children and adolescents age 8 to 17 years with plaque psoriasis (Abstract). 10th ESPD Congress Lausanne Switzerland","volume":"20","author":"Paller","year":"2010","journal-title":"European Journal of Pediatric Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD010017.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jaad.2010.04.004","article-title":"Long-term etanercept in pediatric patients with plaque psoriasis","volume":"63","author":"Paller","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD010017.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","article-title":"Etanercept treatment for children and adolescents with plaque psoriasis","volume":"358","author":"Paller","year":"2008","journal-title":"The New England Journal of Medicine"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD010017.pub2-BIB0010|cit10","first-page":"AB218","article-title":"Etanercept in children and adolescents with psoriasis","volume":"54","author":"Siegfried","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD010017.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaad.2009.10.046","article-title":"Intermittent etanercept therapy in pediatric patients with psoriasis","volume":"63","author":"Siegfried","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD010017.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jssdds.2011.04.005","article-title":"Childhood psoriasis: Analytic retrospective study in Saudi patients","volume":"15","author":"Alsuwaidan","year":"2011","journal-title":"Journal of the Saudi Society of Dermatology & Dermatologic Surgery"},{"issue":"5","key":"10.1002\/14651858.CD010017.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s00105-012-2337-8","article-title":"Etanercept in juvenile psoriasis","volume":"63","author":"Beikert","year":"2012","journal-title":"Hautarzt"},{"key":"10.1002\/14651858.CD010017.pub2-BIB0014|cit14","unstructured":"NCT01090427 A study of the safety and efficacy of ustekinumab in adolescent patients with psoriasis (CADMUS) clinicaltrials.gov\/show\/NCT01090427"},{"key":"10.1002\/14651858.CD010017.pub2-BIB0015|cit15","unstructured":"NCT01100034 Long-term, prospective, observational cohort study of safety and effectiveness of pediatric psoriasis patients treated with etanercept in a naturalistic setting: a post-authorization safety study (PASS) clinicaltrials.gov\/ct2\/show\/NCT01100034"},{"key":"10.1002\/14651858.CD010017.pub2-BIB0016|cit16","unstructured":"EUCTR2009-013072-52-DE A multicentre, randomised, double-dummy, double-blind study evaluating two doses of adalimumab versus methotrexate (MTX) in paediatric subjects with chronic plaque psoriasis (Ps) clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2009-013072-52-DE"},{"key":"10.1002\/14651858.CD010017.pub2-BIB0017|cit17","unstructured":"NCT01251614 A multicenter, randomized, double-dummy, double-blind study evaluating two doses of adalimumab versus methotrexate (MTX) in pediatric subjects with chronic plaque psoriasis (Ps) clinicaltrials.gov\/ct2\/show\/NCT01251614"},{"key":"10.1002\/14651858.CD010017.pub2-BIB0018|cit18","unstructured":"Papp K Thaci D Marcoux D Weibel L Unnebrink K Williams D Efficacy and safety of adalimumab versus methotrexate treatment in pediatric patients with severe chronic plaque psoriasis: results from the 16-week randomized, double-blind period of a phase 3 study [abstract #2970552] 23rd World Congress of Dermatology 2015 Abstracts and Proceedings; 2015 June 8-13; Vancouver 2015"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD010017.pub2-BIB0019|cit19","first-page":"AB190","article-title":"Study design and baseline characteristics from a phase 3, randomized, double-blind study of adalimumab versus methotrexate treatment in pediatric patients with chronic plaque psoriasis (Abstract). 72nd Annual Meeting of the American Academy of Dermatology Denver, CO United States","volume":"70","author":"Papp","year":"2014","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD010017.pub2-BIB0020|cit20","unstructured":"NCT01432249 Post marketing surveillance to observe safety and efficacy of enbrel in pediatric patients with psoriasis clinicaltrials.gov\/ct2\/show\/NCT01432249"},{"issue":"3","key":"10.1002\/14651858.CD010017.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2133.2009.09593.x","article-title":"Epidemiology and comorbidity of psoriasis in children","volume":"162","author":"Augustin","year":"2010","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD010017.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"145-51","DOI":"10.1111\/j.1365-2133.2006.07185.x","article-title":"A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases","volume":"155","author":"Beattie","year":"2006","journal-title":"British Journal of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD010017.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1001\/archderm.1991.01680070084010","article-title":"Incidence of psoriasis in Rochester, Minn, 1980-1983","volume":"127","author":"Bell","year":"1991","journal-title":"Archives of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD010017.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"555-62","DOI":"10.1016\/j.clindermatol.2007.08.009","article-title":"Childhood psoriasis","volume":"25","author":"Benoit","year":"2007","journal-title":"Clinics in Dermatology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD010017.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/03946320140270S101","article-title":"The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases","volume":"27","author":"Blandizzi","year":"2014","journal-title":"International Journal of Immunopathology & Pharmacology"},{"key":"10.1002\/14651858.CD010017.pub2-BIB0026|cit26","unstructured":"Bronckers IM Paller AS van Geel MJ van de Kerkhof PC Seyger MM Psoriasis in children and adolescents: diagnosis, management and comorbidities Paediatric Drugs"},{"issue":"5","key":"10.1002\/14651858.CD010017.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1046\/j.1365-2230.1999.00497.x","article-title":"Management of psoriasis in childhood","volume":"24","author":"Burden","year":"1999","journal-title":"Clinical & Experimental Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD010017.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"302-9","DOI":"10.1038\/cmi.2012.15","article-title":"New insights of T cells in the pathogenesis of psoriasis","volume":"9","author":"Cai","year":"2012","journal-title":"Cellular & Molecular Immunology"},{"issue":"3","key":"10.1002\/14651858.CD010017.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/jid.2010.340","article-title":"Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis","volume":"131","author":"Chiricozzi","year":"2011","journal-title":"Journal of Investigative Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD010017.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1517\/14728222.2014.889686","article-title":"Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target?","volume":"18","author":"Chiricozzi","year":"2014","journal-title":"Expert Opinion in Therapeutic Targets"},{"issue":"6","key":"10.1002\/14651858.CD010017.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2009.06.048","article-title":"Efficacy and safety of treatments for childhood psoriasis: a systematic literature review","volume":"62","author":"Jager","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD010017.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1365-2133.2010.09993.x","article-title":"A cross-sectional study using the Children's Dermatology Life Quality Index (CDLQI) in childhood psoriasis: negative effect on quality of life and moderate correlation of CDLQI with severity scores","volume":"163","author":"Jager","year":"2010","journal-title":"British Journal of Dermatology"},{"issue":"7109","key":"10.1002\/14651858.CD010017.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010017.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1749-6632.2009.05070.x","article-title":"Ustekinumab: lessons learned from targeting interleukin 12\/23p40 in immune-mediated diseases","volume":"1182","author":"Elliott","year":"2009","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD010017.pub2-BIB0035|cit35","unstructured":"European Medicines Agency Assessment report for Enbrel International Nonproprietary Name: Etanercept Procedure No. Type II variation EMEA\/H\/C\/262\/II\/134 www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000262\/WC500113064.pdf"},{"key":"10.1002\/14651858.CD010017.pub2-BIB0036|cit36","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Enbrel (etanercept) Procedure No. EMEA\/H\/C\/000262\/A46\/134CHMP assessment report for paediatric use studies submitted according to Article 46 of the Regulation (EC) No 1901\/2006 www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000262\/WC500137357.pdf"},{"key":"10.1002\/14651858.CD010017.pub2-BIB0037|cit37","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Extension of indication variation assessment report. Humira (adalimumab). Procedure No. EMEA\/H\/C\/000481\/II\/0134 www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000481\/WC500186769.pdf"},{"key":"10.1002\/14651858.CD010017.pub2-BIB0038|cit38","first-page":"2","article-title":"Psoriasis and the pediatric practitioner: emerging therapies","volume":"3","author":"Fallon-Friedlander","year":"2002","journal-title":"Medscape Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD010017.pub2-BIB0039|cit39","first-page":"309","article-title":"Childhood psoriasis","volume":"64","author":"Farber","year":"1999","journal-title":"Cutis"},{"issue":"6","key":"10.1002\/14651858.CD010017.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1067\/mjd.2002.120470","article-title":"Psoriasis of early and late onset: a clinical and epidemiologic study from Spain","volume":"46","author":"Ferr\u00e1ndiz","year":"2002","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD010017.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/jid.2011.304","article-title":"A phase III, randomized, controlled trial of the fully human IL-12\/23 mAb briakinumab in moderate-to-severe psoriasis","volume":"132","author":"Gordon","year":"2012","journal-title":"Journal of Investigative Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD010017.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1525-1470.2010.01292.x","article-title":"Quality of life and clinical features in Swedish children with psoriasis","volume":"28","author":"G\u00e5nemo","year":"2011","journal-title":"Pediatric Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD010017.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/jid.2009.65","article-title":"Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis","volume":"129","author":"Harper","year":"2009","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD010017.pub2-BIB0044|cit44","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"12","key":"10.1002\/14651858.CD010017.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1001\/archderm.143.12.1559","article-title":"Incidence and risk factors for psoriasis in the general population","volume":"143","author":"Huerta","year":"2007","journal-title":"Archives of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD010017.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.crohns.2010.11.001","article-title":"Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect","volume":"5","author":"Iborra","year":"2011","journal-title":"Journal of Crohn's & Colitis"},{"issue":"1","key":"10.1002\/14651858.CD010017.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mjd.2002.120568","article-title":"The immunologic basis for the treatment of psoriasis with new biologic agents","volume":"46","author":"Krueger","year":"2002","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD010017.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/archderm.140.2.218","article-title":"Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis","volume":"140","author":"Krueger","year":"2004","journal-title":"Archives of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD010017.pub2-BIB0049|cit49","first-page":"323","article-title":"Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis","volume":"20","author":"Landells","year":"2010","journal-title":"European Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD010017.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaad.2010.02.060","article-title":"Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial","volume":"64","author":"Langley","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD010017.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/03946320140270S103","article-title":"Adalimumab in the treatment of immune-mediated diseases","volume":"27","author":"Lapadula","year":"2014","journal-title":"International Journal of Immunopathology & Pharmacology"},{"issue":"9","key":"10.1002\/14651858.CD010017.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2165\/00128072-200103090-00005","article-title":"Psoriasis in children, a guide to its diagnosis and management","volume":"3","author":"Leman","year":"2001","journal-title":"Paediatric Drugs"},{"issue":"13","key":"10.1002\/14651858.CD010017.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"The New England Journal of Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010017.pub2-BIB0054|cit54","first-page":"251","article-title":"Etanercept in children and adolescents with psoriasis (Abstract P08. 119). The 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12-15th October 2005","volume":"19","author":"Levy","year":"2005","journal-title":"Journal of the European Academy of Dermatology & Venereology"},{"issue":"6","key":"10.1002\/14651858.CD010017.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","article-title":"The children\u2019s dermatology life quality index (CDLQI): initial validation and practical use","volume":"132","author":"Lewis-Jones","year":"1995","journal-title":"British Journal of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD010017.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/sim.2335","article-title":"Confidence intervals for an exposure adjusted incidence rate difference with applications to clinical trials","volume":"25","author":"Liu","year":"2006","journal-title":"Statistics in Medicine"},{"issue":"8","key":"10.1002\/14651858.CD010017.pub2-BIB0057|cit57","first-page":"975","article-title":"Use of biologic agents in pediatric psoriasis","volume":"9","author":"Marji","year":"2010","journal-title":"Journal of Drugs in Dermatology"},{"key":"10.1002\/14651858.CD010017.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1546-0096-8-18","article-title":"Summary of worldwide pediatric malignancies reported after exposure to etanercept","volume":"8","author":"McCroskery","year":"2010","journal-title":"Pediatric Rheumatology Online Journal"},{"issue":"1","key":"10.1002\/14651858.CD010017.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.0736-8046.2004.21121.x","article-title":"Successful treatment of pediatric psoriasis with infliximab","volume":"21","author":"Menter","year":"2004","journal-title":"Pediatric Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD010017.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"602","DOI":"10.4103\/0378-6323.72445","article-title":"Golimumab and certolizumab: the two new anti-tumor necrosis factor kids on the block","volume":"76","author":"Mittal","year":"2010","journal-title":"Indian Journal of Dermatology, Venereology & Leprology"},{"key":"10.1002\/14651858.CD010017.pub2-BIB0061|cit61","unstructured":"National Institute for Health and Clinical Excellence Psoriasis assessment and management of psoriasis. Clinical guideline methods, evidence and recommendations. October 2012 www.nice.org.uk\/guidance\/cg153"},{"issue":"2","key":"10.1002\/14651858.CD010017.pub2-BIB0062|cit62","first-page":"AB195","article-title":"A 12 week phase 3 study of efficacy and safety of etanercept therapy in children and adolescents with moderate to severe plaque psoriasis (Abstract P2783). American Academy of Dermatology 65th Annual Meeting February 2-6, 2007","volume":"56","author":"Paller","year":"2007","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD010017.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jaad.2010.04.004","article-title":"Long-term etanercept in pediatric patients with plaque psoriasis","volume":"63","author":"Paller","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD010017.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/j.jaad.2009.11.001","article-title":"Subgroup analyses of etanercept in pediatric patients with psoriasis","volume":"63","author":"Paller","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD010017.pub2-BIB0065|cit65","first-page":"52","article-title":"Interim results of a long-term safety and tolerability study of etanercept treatment in children and adolescents age 8 to 17 years with plaque psoriasis (Abstract). 10th ESPD Congress Lausanne Switzerland","volume":"20","author":"Paller","year":"2010","journal-title":"European Journal of Pediatric Dermatology"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD010017.pub2-BIB0066|cit66","first-page":"AB11","article-title":"Safety and efficacy of etanercept treatment in children and adolescents with plaque psoriasis: 96-week results of open-label extension study. Conference: 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL United States. Conference Start: 20100305 Conference End: 20100309","volume":"62","author":"Paller","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"13","key":"10.1002\/14651858.CD010017.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"The New England Journal of Medicine"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD010017.pub2-BIB0068|cit68","first-page":"AB190","article-title":"Study design and baseline characteristics from a phase 3, randomized, double-blind study of adalimumab versus methotrexate treatment in pediatric patients with chronic plaque psoriasis (Abstract). 72nd Annual Meeting of the American Academy of Dermatology Denver, CO United States","volume":"70","author":"Papp","year":"2014","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD010017.pub2-BIB0069|cit69","unstructured":"Papp K Thaci D Marcoux D Weibel L Unnebrink K Williams D Efficacy and safety of adalimumab versus methotrexate treatment in pediatric patients with severe chronic plaque psoriasis: results from the 16-week randomized, double-blind period of a phase 3 study [abstract #2970552] 23rd World Congress of Dermatology 2015 Abstracts and Proceedings; 2015 June 8-13; Vancouver 2015"},{"issue":"2","key":"10.1002\/14651858.CD010017.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1111\/j.1468-3083.2012.04585.x","article-title":"Induction phase, primary endpoint, time to decide on primary failure, and therapeutic goals in biologic treatment of psoriasis","volume":"27","author":"Puig","year":"2013","journal-title":"Journal of the European Academy of Dermatology & Venereology"},{"issue":"6","key":"10.1002\/14651858.CD010017.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"565-70","DOI":"10.1111\/j.1365-2133.1991.tb04952.x","article-title":"Measurement of involved surface area in patients with psoriasis","volume":"124","author":"Ramsay","year":"1991","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD010017.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"174-8","DOI":"10.1046\/j.1525-1470.2000.01746.x","article-title":"A comparative study of pediatric onset psoriasis with adult onset psoriasis","volume":"17","author":"Raychaudhuri","year":"2000","journal-title":"Pediatric Dermatology"},{"key":"10.1002\/14651858.CD010017.pub2-BIB0073|cit73","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"12","key":"10.1002\/14651858.CD010017.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochemical Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD010017.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1442-200X.2006.02270.x","article-title":"Psoriasis in childhood and adolescence: evaluation of demographic and clinical features","volume":"48","author":"Seyhan","year":"2006","journal-title":"Pediatrics International"},{"issue":"5","key":"10.1002\/14651858.CD010017.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/10543400903105463","article-title":"Statistical methods to analyze adverse events data of randomized clinical trials","volume":"19","author":"Siddiqui","year":"2009","journal-title":"Journal of Biopharmaceutical Statistics"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD010017.pub2-BIB0077|cit77","first-page":"AB218","article-title":"Etanercept in children and adolescents with psoriasis (Abstract P2880). American Academy of Dermatology 64th Annual Meeting March 3-7, 2006","volume":"54","author":"Siegfried","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD010017.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaad.2009.10.046","article-title":"Intermittent etanercept therapy in pediatric patients with psoriasis","volume":"63","author":"Siegfried","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD010017.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2147\/TCRM.S4908","article-title":"Pediatric psoriasis: an update","volume":"5","author":"Silverberg","year":"2009","journal-title":"Therapeutics & Clinical Risk Management"},{"issue":"4","key":"10.1002\/14651858.CD010017.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/jid.2009.391","article-title":"How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review","volume":"130","author":"Spuls","year":"2010","journal-title":"Journal of Investigative Dermatology"},{"issue":"10","key":"10.1002\/14651858.CD010017.pub2-BIB0081|cit81","first-page":"815","article-title":"Therapy of psoriasis in childhood and adolescence - a German expert consensus","volume":"9","author":"Sticherling","year":"2011","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft"},{"issue":"10","key":"10.1002\/14651858.CD010017.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1038\/jid.2010.164","article-title":"Critical appraisal of quality of clinical practice guidelines for treatment of psoriasis vulgaris, 2006-2009","volume":"130","author":"Tan","year":"2010","journal-title":"Journal of Investigative Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD010017.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jaad.2009.07.029","article-title":"Incidence of psoriasis in children: a population-based study","volume":"62","author":"Tollefson","year":"2010","journal-title":"Journal of the American Academy Dermatology"},{"key":"10.1002\/14651858.CD010017.pub2-BIB0084|cit84","unstructured":"US Food Drug Administration Information for healthcare professionals: tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi) www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm174474.htm"},{"key":"10.1002\/14651858.CD010017.pub2-BIB0085|cit85","unstructured":"US Food Drug Administration Enbrel (etanercept) prescribing information December 2012 www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/ucm334668.htm"},{"issue":"5","key":"10.1002\/14651858.CD010017.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.clindermatol.2003.08.015","article-title":"Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis","volume":"21","author":"Victor","year":"2003","journal-title":"Clinics in Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD010017.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archdermatol.2011.263","article-title":"Trends in pediatric psoriasis outpatient health care delivery in the United States","volume":"148","author":"Vogel","year":"2012","journal-title":"Archives of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD010017.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0928-0987(01)00222-6","article-title":"Biopharmaceuticals and biotechnology medicines: an issue of nomenclature","volume":"15","author":"Walsh","year":"2002","journal-title":"European Journal of Pharmaceutical Sciences"},{"issue":"4","key":"10.1002\/14651858.CD010017.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1476-5381.2010.00702.x","article-title":"Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents","volume":"160","author":"Weger","year":"2010","journal-title":"British Journal of Pharmacology"},{"issue":"8","key":"10.1002\/14651858.CD010017.pub2-BIB0090|cit90","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010017","article-title":"Anti-TNF agents for paediatric psoriasis","author":"Sanclemente","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010017.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T06:07:31Z","timestamp":1663999651000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010017.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Skin Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,11,24]]},"references-count":90,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010017.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,24]]}}}